Skip to main content
Equibles
LIPO logo

LIPO · Lipella Pharmaceuticals Inc.

Track LIPO — free

Use LIPO with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.00 +0.00 (+0.00%) At close · Sep 2
Rebalance outlook locked
Going-concern doubt — flagged Nov 14, 2025

Substantial doubt about the company's ability to continue as a going concern.

“These factors individually and collectively raise substantial doubt about the Company's ability to continue as a going concern. The accompanying unaudited condensed financial statements do not include any adjustments that may result from this uncertainty.”
View the 10-Q filed Nov 14, 2025
Market Cap
$2,310
Shares
4.62M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.00 Open$0.00 Day$0.00–0.00 52W close$0.00–0.64 Avg vol 30d44K Short int3K · 0.1% float · 6.4d Short vol99% DataNov 2024–Sep 2026 Filing10-Q · Nov 14

Raw chart and full-history price indicators begin at the captured split on Nov 8, 2024; bars on opposite sides are not compared.

Up next

Latest filing: 10-Q
filed Nov 14, 2025

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$389,783
Trailing 12 months
Net income (TTM)
−$5.33M
Trailing 12 months
Revenue growth YoY
-36.4%
Year over year
Operating margin
-947.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+306.5%
Year over year · more shares
Price change (1Y)
-99.9%
Trailing year
Short interest
0.1%
Latest settlement · 6.4 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.47
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −100%
below
Price vs 50-day avg −99%
below
RSI (14) 36
neutral
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −99%
trailing
6-month return −100%
trailing
YTD return −100%
this year
Relative strength −115%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.06% of float · ▲ +3.9% MoM · 6.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
4 holders — mid 2-yr range
Squeeze score 33
low risk · 0–100
Fundamentals
Strong
Revenue growth +19%
Y/Y
EPS growth +22%
Y/Y
Free cash flow $-4.0M
Quant / Vol
risk profile
Very High
Volatility 430%
annualized · 1-yr
Max drawdown −100%
past year
ATR 2420.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−100% Bearish
Price vs 50-day avg
−99% Bearish
RSI (14)
36 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.06% of float · ▲ +3.9% MoM · 6.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
4 holders — mid 2-yr range
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $1
vs 200-day avg -100% vs 50-day avg -99%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
LIPO
Lipella Pharmaceuticals Inc.
this stock
$2,310 -99.7% +19.3% — 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $140.51B +23.1% +46.2% 32.3 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $84.82B +9.3% +20.8% 20.4 2.3%
ARGX
Argenx SE
 $65.63B +25.3% — — 1.9%
CSLLY
Csl Ltd
 $59.96B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
4
% held
0.1%
Net QoQ
-10.6K sh
Top holder
Tower Research Capital LL…
Held Float
View
Short & Settlement
Short Interest Rising
Shares short
2.6K
Days to cover
6.4d
Change
+99 sh
View
Short Volume
Short vol %
99%
As of
Sep 1, 2026
Short Total
View
Fails to Deliver
FTD shares
1.4K
Value
$236
As of
May 20, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
Jul 13, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$536.4K
Net income (FY)
$-5.0M
EPS diluted
$-4.79
View
Filings
SEC Filings
Latest
8-K
Filed
Jul 15, 2026
This year
3
View
Exempt Offerings
Offering
$9.0K
Filed
Apr 1, 2025
View

Performance

Raw-price comparisons begin at the captured split on Nov 8, 2024; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
LIPO +25.0% -99.1% -99.8% +25.0% -99.7%
SPY -0.1% -0.6% +14.9% -0.3% +12.2%
vs SPY +25.1% -98.5% -114.6% +25.3% -111.9%
Key facts CIK 1347242 CUSIP 53630L209 Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)